Dr. Julian Prosia is the CEO of Ophthalogix Canada, a company specializing in advanced treatments for dry eye and ocular surface disease. As a leading innovator in amniotic membrane therapy, Dr. Prosia has introduced Canada’s first doctor-owned amniotic membrane company and has personally performed over 2,000 amniotic membrane procedures while managing more than 50,000 dry eye cases nationwide. Beyond his clinical expertise, Dr. Prosia is a respected educator and speaker, known for training fellow optometrists and their staff in integrating regenerative medicine into everyday practice, and he is currently involved in pioneering research on nerve regeneration for ocular pain.

In this episode…

Most eye conditions are managed, not truly healed. But what if we could actually regenerate the ocular surface instead of just maintaining it?

Drawing from his experience as a leading expert in ocular surface disease, Dr. Julian Prosia explains that true healing starts by addressing inflammation and nerve dysfunction at the root. He highlights how amniotic membrane therapy delivers growth factors that accelerate healing, reduce scarring, and even support nerve regeneration. The result is a shift from temporary relief to long-term restoration, fundamentally changing how clinicians approach stubborn ocular surface conditions.

In this episode of Cleinman Connect Podcast's Optometrist Unleashed series, Dr. Trevor Miranda is joined by Dr. Julian Prosia, CEO of Ophthalogix Canada, to discuss healing the ocular surface through regenerative medicine. Dr. Prosia outlines how amniotic membrane therapy works, when to use it in practice, and its role in managing dry eye and corneal disease. He also shares advice on implementing this technology efficiently in everyday optometry.